AUTHOR=Popa-Fotea Nicoleta-Monica , Ferdoschi Corina-Elena , Micheu Miruna-Mihaela 

TITLE=Molecular and cellular mechanisms of inflammation in atherosclerosis

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=Volume 10 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1200341

DOI=10.3389/fcvm.2023.1200341

ISSN=2297-055X

ABSTRACT=Atherosclerosis and its complications are a major cause of morbidity and mortality worldwide in spite of the improved medical and invasive treatment in terms of revascularization. Atherosclerosis is a dynamic, multi-step process in which inflammation is an ubiquitous component participating in the initiation, development and entanglements of the atherosclerotic plaque. Immune system, either native or acquired, after activation is part of the atherosclerotic dynamics enhancing the pro-atherogenic function of immune or non-immune cells, such as endothelial, smooth muscle cells or platelets, through mediators such as cytokines or directly by cell-to-cell interaction. Cytokines are molecules secreted by the activated cells mentioned above that mediate the inflammatory component of atherosclerosis whose function is to stimulate the immune cells and as well as the production of further cytokines. This review provides insights of the cell axes activation, and specific mechanisms and pathways through which inflammation actuate atherosclerosis. Mis en forme : Taquets de tabulation : 10,5 cm,Gauche Code de champ modifié 79 Cardiovascular Outcomes Research with PCSK9 Inhibition in 80 Subjects With Elevated Risk) depicted that despite a reduction of low 81 density lipoprotein (LDL)-cholesterol at values lower than 30 mg/dl, 82 those subjects with elevated hsCRP showed a higher incidence of 83 major adverse cardiac events (MACE) compared with subjects with 84 LDL-cholesterol >100 mg/dL, despite the use of PCSK9 inhibitors 85 (6). The above studies proved that despite state-of-the-art treatment 86 with intensive reduction of the LDL-cholesterol and lifestyle 87 changes, subjects with ACS have a residual inflammatory risk as high 88 as 60% if hsCRP is increased, as shown in SPIRE 1 and 2 (Studies of 89 PCSK9 Inhibition and the Reduction in Vascular Events) trials (7). 90 Code de champ modifié Code de champ modifié Code de champ modifié Mis en forme : Anglais (E.U.